The application provides biocompatible carriers comprising bone forming and/or cartilage forming cells and methods for making them. The application further provides pharmaceutical compositions comprising said ATMPs and method of treatments using said ATMPs. The application further relates to said ATMPS for use in the treatment of bone disorders, cartilage disorders and joint disorders. The current invention further relates to method of treatments of bone disorders, cartilage disorders and joint disorders.

The invention relates to compounds of formula (I): ##STR00001##
or a salt thereof, wherein R.sup.1, R.sup.5, R.sup.7, R.sup.8, X, m, n, p and q are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating tissue specific fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

The invention relates to compounds of formula (I): ##STR00001##
or a salt thereof, wherein R.sup.1, R.sup.5, R.sup.7, R.sup.8, X, m, n, p and q are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating tissue specific fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

Provided herein are methods and compositions for long term treatment of spinal pain. In particular, use of double-stranded oligonucleotide decoys capable of binding to the DNA binding sites of two transcription factors are provided for treatment of spinal pain for over seven days, where the decoys are administered without a drug delivery system.

Provided herein are methods and compositions for long term treatment of spinal pain. In particular, use of double-stranded oligonucleotide decoys capable of binding to the DNA binding sites of two transcription factors are provided for treatment of spinal pain for over seven days, where the decoys are administered without a drug delivery system.

The disclosure provides nonsteroidal anti-inflammatory compositions and methods of use thereof. Specifically, the disclosure provides cell-free or substantially cell-free regenerative nonsteroidal anti-inflammatory compositions derived from placenta and/or from MSC cells isolated therefrom, methods for producing said compositions, and uses thereof to treat chronic and acute inflammatory conditions and diseases.

The disclosure provides nonsteroidal anti-inflammatory compositions and methods of use thereof. Specifically, the disclosure provides cell-free or substantially cell-free regenerative nonsteroidal anti-inflammatory compositions derived from placenta and/or from MSC cells isolated therefrom, methods for producing said compositions, and uses thereof to treat chronic and acute inflammatory conditions and diseases.

A drug product comprising a combination of highly purified collagenase I and collagenase II from Clostridium histolyticum is disclosed. The drug product includes collagenase I and collagenase II in a ratio of about 1 to 1, with a purity of greater than at least 95%. The invention further disclosed improved fermentation and purification processes for preparing the said drug product.

The present disclosure relates to a composition for the prevention, improvement, or treatment of cartilage-related diseases or symptoms, the composition including hyaluronan and proteoglycan link protein 1 (HAPLN1) as an active ingredient. In detail, the present disclosure provides a composition for regenerating cartilage, a composition for the prevention, improvement, or treatment of osteoarthritis, or a composition for regenerating growth plate cartilage, each composition including HAPLN1 as an active ingredient.

The present disclosure relates to a composition for the prevention, improvement, or treatment of cartilage-related diseases or symptoms, the composition including hyaluronan and proteoglycan link protein 1 (HAPLN1) as an active ingredient. In detail, the present disclosure provides a composition for regenerating cartilage, a composition for the prevention, improvement, or treatment of osteoarthritis, or a composition for regenerating growth plate cartilage, each composition including HAPLN1 as an active ingredient.